Compare Stocks → The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADXNNASDAQ:CWBRNASDAQ:LIXTNASDAQ:UNCY Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$15.55-17.0%$14.34$5.00▼$27.90$16.48M1.6616,868 shs11,507 shsCWBRCohBar$0.80-11.1%$0.82$0.51▼$6.90$2.33M1.543,282 shs358 shsLIXTLixte Biotechnology$3.28+1.9%$2.84$1.58▼$9.50$7.38M-0.28451,868 shs16,082 shsUNCYUnicycive Therapeutics$1.04-2.8%$1.39$0.47▼$1.82$36.15M2.66355,833 shs179,329 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics-17.02%-29.32%+31.84%+48.66%+3.67%CWBRCohBar-11.15%-11.14%+5.24%+1.23%-54.29%LIXTLixte Biotechnology-4.65%-1.50%+45.45%+58.45%-46.23%UNCYUnicycive Therapeutics-2.80%-9.96%-31.58%+11.83%-29.73%Biden replacement revealed? (Ad)A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new reportMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXNAddex Therapeutics0.7271 of 5 stars0.05.00.00.02.40.80.6CWBRCohBarN/AN/AN/AN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/AN/AN/AN/AUNCYUnicycive Therapeutics1.9676 of 5 stars3.53.00.00.00.62.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics2.00HoldN/AN/ACWBRCohBarN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AUNCYUnicycive Therapeutics3.00Buy$5.30409.62% UpsideCurrent Analyst RatingsLatest LIXT, ADXN, UNCY, and CWBR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2024UNCYUnicycive TherapeuticsBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSpeculative Buy ➝ Speculative Buy$3.004/4/2024UNCYUnicycive TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$9.004/1/2024UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.503/14/2024UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.503/5/2024UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.502/14/2024UNCYUnicycive TherapeuticsNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$6.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$1.80M9.16N/AN/A$1.20 per share12.96CWBRCohBarN/AN/AN/AN/A$5.27 per shareN/ALIXTLixte BiotechnologyN/AN/AN/AN/A$0.22 per shareN/AUNCYUnicycive Therapeutics$680K53.16N/AN/A($0.11) per share-9.45Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics-$11.76M-$19.27N/AN/AN/A-653.33%-277.44%-156.74%5/9/2024 (Estimated)CWBRCohBar-$12.18M-$4.36N/A∞N/AN/AN/AN/A5/13/2024 (Estimated)LIXTLixte Biotechnology-$5.09M-$2.70N/A∞N/AN/A-1,202.60%-119.91%5/8/2024 (Estimated)UNCYUnicycive Therapeutics-$30.54M-$1.55N/AN/AN/AN/AN/A-96.37%5/21/2024 (Estimated)Latest LIXT, ADXN, UNCY, and CWBR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023UNCYUnicycive Therapeutics-$0.18-$0.16+$0.02-$0.16N/AN/A3/19/2024Q4 2023LIXTLixte BiotechnologyN/A-$0.41-$0.41-$0.41N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/ACWBRCohBarN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A1.461.46CWBRCohBarN/AN/AN/ALIXTLixte BiotechnologyN/A13.7213.72UNCYUnicycive TherapeuticsN/A0.760.76OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%CWBRCohBar2.47%LIXTLixte Biotechnology5.10%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%CWBRCohBar6.51%LIXTLixte Biotechnology15.50%UNCYUnicycive Therapeutics42.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics241.06 million901,000Not OptionableCWBRCohBar92.91 million2.72 millionNot OptionableLIXTLixte Biotechnology32.25 million1.90 millionNot OptionableUNCYUnicycive Therapeutics1234.76 million20.16 millionNot OptionableLIXT, ADXN, UNCY, and CWBR HeadlinesSourceHeadlineUnicycive Therapeutics (NASDAQ:UNCY) Given "Speculative Buy" Rating at Benchmarkamericanbankingnews.com - April 16 at 3:34 AMBuy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial Positioningmarkets.businessinsider.com - April 12 at 1:16 PMUnicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conferenceglobenewswire.com - April 10 at 7:03 AMUnicycive Therapeutics: A Strong Buy on OLC’s Potential to Revolutionize Hyperphosphatemia Treatment in CKDmarkets.businessinsider.com - April 4 at 4:58 PMBuy Rating Affirmed for Unicycive Therapeutics Amidst Positive Milestones and Solid Financial Footingmarkets.businessinsider.com - April 2 at 4:34 AMUNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q4 2023investorplace.com - March 28 at 11:31 PMUnicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Updatefinance.yahoo.com - March 28 at 8:12 PMUnicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 28 at 4:15 PMUnicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congressglobenewswire.com - March 25 at 7:03 AMUnicycive reports progress in kidney injury treatment trialinvesting.com - March 16 at 12:26 AMBuy Rating on Unicycive Therapeutics Amidst Promising UNI-494 Drug Candidate Prospectsmarkets.businessinsider.com - March 14 at 3:38 PMUnicycive Announces $50 Million Private Placementglobenewswire.com - March 14 at 7:03 AMUnicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conferenceglobenewswire.com - March 13 at 7:03 AMUnicycive Therapeutics, Inc.: Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)finanznachrichten.de - March 9 at 1:24 AMUnicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)globenewswire.com - March 7 at 4:12 PMBuy Rating Affirmed for Unicycive Therapeutics Amidst Promising UNI-494 Developments and FDA Orphan Drug Designationmarkets.businessinsider.com - March 6 at 4:12 PMUnicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patientsglobenewswire.com - March 4 at 7:03 AMUnicycive Therapeutics Stock (NASDAQ:UNCY), Short Interest Reportbenzinga.com - February 25 at 9:25 AMUnicycive Therapeutics Stock (NASDAQ:UNCY), Analyst Ratings, Price Targets, Predictionsbenzinga.com - February 25 at 9:25 AMUnicycive Therapeutics (UNCY) Price Target Increased by 14.13% to 4.46msn.com - February 24 at 11:54 PMUnicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meetingfinance.yahoo.com - February 14 at 9:33 AMUnicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meetingglobenewswire.com - February 14 at 7:03 AMWe're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Ratefinance.yahoo.com - February 6 at 8:24 AMUnicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conferencefinance.yahoo.com - January 29 at 8:42 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAddex TherapeuticsNASDAQ:ADXNAddex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.CohBarNASDAQ:CWBRCohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.Lixte BiotechnologyNASDAQ:LIXTLixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.Unicycive TherapeuticsNASDAQ:UNCYUnicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.